Joint EASO–ADA Webinar: Applying Frameworks for Obesity Care in Europe

Webinar Online
11:00 - 17:45 CET

Join the Royal Society of Medicine (RSM) Food and Health Forum for this full day webinar exploring the relationship between diet, neurobehavioural function and GLP-1 receptor agonist (GLP-1 RA) therapy. Bringing together leading experts in obesity, metabolism, nutrition and neurobiology, the programme will examine how diet influences health outcomes, weight trajectories and brain function during and after treatment, while addressing some of the most important unanswered questions in obesity care.

The use of GLP-1 receptor agonists has transformed the treatment landscape for obesity and metabolic disease. However, despite rapidly growing use, there remains little clear evidence-based dietary guidance to support patients during treatment or after therapy ends. At the same time, clinicians and researchers continue to explore the longer-term effects of these treatments on appetite regulation, reward processing, eating behaviour and weight regain following cessation. As newer dual and triple agonists emerge and oral therapies increase access to treatment, understanding these issues is becoming increasingly important for clinical practice.

Why attend?

  • Hear from internationally recognised experts including Professor John Wilding, Dr Dimitris Koutoukidis, Professor Jens Juul Holst, and Professor Susan Ozanne
  • Explore current evidence on diet, health outcomes and weight management during and after GLP-1 receptor agonist therapy
  • Gain insight into the neurobiological mechanisms underlying appetite regulation, reward pathways and eating behaviour, and explore the challenges associated with treatment cessation and weight regain
  • Understand how emerging dual and triple agonist therapies may influence future obesity management
  • Put your questions directly to expert panels during dedicated discussion sessions

Aims of the event

  • Provide an evidence-based overview of diet and neurobehavioural function during and after GLP-1 receptor agonist therapy
  • Explore the metabolic, behavioural and clinical factors influencing treatment outcomes and cessation
  • Support healthcare professionals in applying emerging evidence to obesity management and patient care

Learning outcomes
By attending this webinar, participants will be able to:

  • Evaluate current perspectives on GLP-1 receptor agonist therapies in obesity management, including their role as long-term metabolic tools
  • Describe the neurobiological and behavioural mechanisms associated with appetite regulation, reward pathways and eating behaviour during GLP-1 therapy
  • Evaluate emerging evidence on diet, treatment cessation, weight regain and future approaches to obesity management

Who should attend?
This webinar is suitable for:

  • Obesity specialists, endocrinologists and metabolic medicine physicians
  • Dietitians, nutritionists and advanced practitioners in weight management
  • Clinical psychologists and neuropsychologists working in eating behaviour and obesity
  • Academic researchers working across obesity, nutrition, neurobiology and metabolic health
  • Healthcare professionals with an interest in GLP-1 therapies, treatment cessation and weight management
  • Industry stakeholders including pharmaceutical developers, digital health companies and nutrition and food sector professionals with an interest in metabolic health innovation